A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
Authors:
- Sooyeon OhSOSooyeon Oh
- YoungJoon ParkYPYoungJoon Park
- Hyun-Jung LeeHLHyun-Jung Lee
- Jooho LeeJLJooho Lee
- Soo-Hyeon LeeSLSoo-Hyeon Lee
- Young-Seok BaekYBYoung-Seok Baek
- Su-Kyung ChunSCSu-Kyung Chun
- Seung-Min LeeSLSeung-Min Lee
- Mina KimMKMina Kim
- Young-Eun ChonYCYoung-Eun Chon
- Yeonjung HaYHYeonjung Ha
- Yuri ChoYCYuri Cho
Open Access
Abstract
The chemotherapeutics sorafenib and regorafenib inhibit shedding of MHC class I-related chain A (MICA) from hepatocellular carcinoma (HCC) cells by suppressing a disintegrin and metalloprotease 9 (ADAM9). MICA is a ligand for natural killer (NK) group 2 member D (NKG2D) and is expressed on tumor cells to elicit attack by NK cells. This study measured ADAM9 mRNA levels in blood samples of advanced HCC patients (n = 10). In newly diagnosed patients (n = 5), the plasma ADAM9 mRNA level was significantly higher than that in healthy controls (3.001 versus 1.00, p < 0.05). Among four patients treated with nivolumab therapy, two patients with clinical response to nivolumab showed significant decreases in fold changes of serum ADAM9 mRNA level from 573.98 to 262.58 and from 323.88 to 85.52 (p < 0.05); however, two patients with no response to nivolumab did not. Using the Cancer Genome Atlas database, we found that higher expression of ADAM9 in tumor tissues was associated with poorer survival of HCC patients (log-rank p = 0.00039), while ADAM10 and ADAM17 exhibited no such association. In addition, ADAM9 expression showed a positive correlation with the expression of inhibitory checkpoint molecules. This study, though small in sample size, clearly suggested that ADAM9 mRNA might serve as biomarker predicting clinical response and that the ADAM9-MICA-NKG2D system can be a good therapeutic target for HCC immunotherapy. Future studies are warranted to validate these findings.Keywords
Funding Information
- Gyeonggi-Incheon study group of the Korean Association for the Study of the Liver. (not applicable)
This publication has 63 references indexed in Scilit:
- Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular CarcinomaPLOS ONE, 2012
- microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinomaFEBS Letters, 2011
- Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinomaNature Genetics, 2011
- Sorafenib inhibits the shedding of major histocompatibility complex class I–related chain A on hepatocellular carcinoma cells by down‐regulating a disintegrin and metalloproteinase 9†Hepatology, 2010
- Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Tumor-Associated MICA Is Shed by ADAM ProteasesCancer Research, 2008
- Angiotensin II and epidermal growth factor receptor cross‐talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell linesHepatology Research, 2008
- The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinasesInternational Journal of Cancer, 2006
- Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acidInternational Journal of Cancer, 2003
- Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary reportCancer, 1991